Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses
Research and development	$ 6,608,392	$ 6,645,417
General and administrative	7,999,000	10,620,008
Total operating expenses	14,607,392	17,265,425
Operating loss	(14,607,392)	(17,265,425)
Change in fair value of common stock warrants	(2,332,567)
Warrant financing expense	(938,794)
Other income	50,801	25,648
Loss before income taxes	(17,827,952)	(17,239,777)
Income taxes	0	0
Net loss	(17,827,952)	(17,239,777)
Deemed dividend attributable to preferred stock	(4,502,799)
Net loss applicable to common shareholders	$ (22,330,751)	$ (17,239,777)
Loss per common share - basic and diluted (in dollars per share)	$ (1.97)	$ (2.03)
Weighted average shares outstanding - basic and diluted (in shares)	11,308,532	8,496,964